药明康德上调全年业绩指引 整体收入最高至435亿元

智通财经
28 Jul
【药明康德上调全年业绩指引 整体收入最高至435亿元】2025年7月28日,药明康德(603259.SH/2359.HK)披露了2025年度中期报告。根据报告显示,在收获上半年收入及利润均实现两位数同比增长的同时,公司将进一步上调全年业绩指引。预计2025年持续经营业务收入重回双位数增长,增速从年初所设定的10~15%上调至13~17%,即公司整体收入从415~430亿上调至425~435亿;自由现金流从年初所设定的40~50亿上调至50~60亿元。并指出,有信心在2025年进一步提升经调整non-IFRS归母净利润水平。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10